Intellectual property (IP) is a significant factor in market competition. Patents protect new drugs, giving companies exclusive rights to market their innovations for a certain period. This exclusivity allows firms to recoup their R&D investments but also leads to high drug prices. Once patents expire, generic versions can enter the market, increasing competition and reducing prices. The balance between patent protection and generic competition is a critical aspect of the market dynamics in cancer treatment.
